BioSpace News Archive

Mainz Biomed N.V. announced a strategic partnership with Ärztliches Labor Dr. Buhlmann, a move aimed at further strengthening its position in the German market.

invIOs GmbH announces that it has started patient recruitment for a Phase 1b trial of its novel autologous cell therapy, APN401, in patients with solid tumors, and has successfully secured grant funding.

Sinovac Biotech Ltd. announced that its Board of Directors unanimously determined that the partial tender offer by Alternative Liquidity Index LP to acquire up to 10,000,000 common shares of Sinovac for $0.03 per share in cash is NOT advisable and is NOT in the best interests of the Company or its shareholders.

4P-Pharma is thrilled to achieve a significant milestone in its history.

Italfarmaco Group announced that its Marketing Authorization Application for Givinostat as a potential treatment for Duchenne Muscular Dystrophy has been submitted to the European Medicine Agency and that the EMA has started its regulatory review process.

NUCLIDIUM announced the presentation of pre-clinical and clinical translation data from three of the company’s precision oncology programs targeting epithelial tumours, neuroendocrine tumours and prostate cancer at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine, 09-13 September 2023.

Addex Therapeutics announced that the ADX71149 Phase 2 epilepsy clinical study is progressing well, with Cohort 1 completed and 80% of patients recruited into Cohort 2.

Roche – The Economist Impact report, Advancing the Frontier of Health and Technology Integration: The 2023 Digital Health Barometer, commissioned by Roche Diagnostics, examines the digital health environment in and across ten diverse countries from advanced economies to emerging markets: Australia, Brazil, France, Germany, Japan, Mexico, South Korea, Spain, the UK and the US.

ACM Biolabs, a biotechnology company using its next-generation polymer-based delivery platform to develop new nano formulations for use in multiple therapeutic fields, announced positive topline results from a Phase I trial of ACM-001, the Company’s first clinical-stage development program.

International medical imaging IT and cybersecurity company Sectra’s contracted order bookings exceeded SEK 2.9 billion during the quarter.